Kadmon Holdings, Inc. (KDMN)
(Delayed Data from NYSE)
$2.33 USD
+0.08 (3.56%)
Updated May 3, 2019 04:02 PM ET
After-Market: $2.32 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
[KDMN]
Reports for Purchase
Showing records 1 - 20 ( 36 total )
Industry: Medical - Biomedical and Genetics
Price: 25.00
Industry: Medical - Biomedical and Genetics
REZUROCK Looks to Rock its? Launch; Reit Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
REZUROCK Approved For cGVHD, Investor Focus Now Shifts to Launch
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
Refining Revenue Expectations Ahead of August PDUFA; Reit Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
Commercial Launch Preparation Underway Ahead of PDUFA in 3Q21; Reit Buy and $20 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
Revising Revenues in Light of PDUFA Extension; Reit Buy and Lowering PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
Maintaining Our Ground; Believe Amendment Not Impactful For Belumosudil Approvability
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
A PDUFA Date Away From Commercial Launch; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
Novel Anti-PD-L1/IL-15 Fusion Marks Initial Foray into I/O
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
Momentum Continues for Belumosudil With Positive ROCKstar Data at ASH 2020
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
Multiple Catalysts and Milestones Expected in 1Q21, Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
Our Thoughts Around Market Potential in cGVHD Ahead of Approval; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
Price: 10.00
Industry: Medical - Biomedical and Genetics
Participation in RTOR Points to Potential Approval in 1Q21; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
Positive Regulatory Feedback Reaffirms KD025 NDA Submission in 4Q20; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Price: 150.00
Industry: Medical - Biomedical and Genetics
Pre-NDA Meeting This Month Should Frame Timeline to Regulatory Approval; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 25.00
Industry: Medical - Biomedical and Genetics
Believe KD025-213 Interim Data Supports Potential FDA Approval in the Near-Term
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
Believe Risk Return Profile Is Attractive Heading Into KD025-213 Interim Data ; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Price: 10.00
Industry: Medical - Biomedical and Genetics
Price: 25.00